Chlamydial Antibiotic Resistance and Treatment Failure in Veterinary and Human Medicine

被引：61
作者：
Borel N. [1 ]
Leonard C. [1 ]
Slade J. [2 ]
Schoborg R.V. [2 ]
机构：
[1] Institute of Veterinary Pathology, Department of Pathobiology, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 268, Zurich
[2] Department of Biomedical Sciences, Center of Excellence for Inflammation, Infectious Disease and Immunity, Box 70579, Quillen College of Medicine, East Tennessee State University, Box 70579, Johnson City, 37614-0579, TN
来源：
Current Clinical Microbiology Reports | 2016年 / 3卷 / 1期
关键词：
Chlamydia muridarum; Chlamydia suis; Chlamydia trachomatis; Gastrointestinal infection; Tetracycline resistance; Treatment failure;
D O I：
10.1007/s40588-016-0028-4
中图分类号：
学科分类号：
摘要：
The Chlamydiaceae are widespread pathogens of both humans and animals. Chlamydia trachomatis infection causes blinding trachoma and reproductive complications in humans. Chlamydia pneumoniae causes human respiratory tract infections and atypical pneumonia. Chlamydia suis infection is associated with conjunctivitis, diarrhea, and failure to gain weight in domestic swine. Chlamydial infections in humans and domesticated animals are generally controlled by antibiotic treatment—particularly macrolides (usually azithromycin) and tetracyclines (tetracycline and doxycycline). Tetracycline-containing feed has also been used to limit infections and promote growth in livestock populations, although its use has decreased because of growing concerns about antimicrobial resistance development. Because Sandoz and Rockey published an elegant review of chlamydial anti-microbial resistance in 2010, we will review the following: (i) antibiotic resistance in C. suis, (ii) recent evidence for acquired resistance in human chlamydial infections, and (iii) recent non-genetic mechanisms of antibiotic resistance that may contribute to treatment failure. © 2016, The Author(s).
引用
收藏
页码：10 / 18
页数：8
相关论文
共 85 条
[41]  
Batteiger B.E., Tu W., Ofner S., Van Der Pol B., Stothard D.R., Orr D.P., Et al., Repeated Chlamydia trachomatis genital infections in adolescent women, J Infect Dis, 201, pp. 42-51, (2010)
[42]  
Horner P.J., Azithromycin antimicrobial resistance and genital Chlamydia trachomatis infection: duration of therapy may be the key to improving efficacy, Sex Transm Infect, 88, pp. 154-156, (2012)
[43]  
Pitt R.A., Alexander S., Horner P.J., Ison C.A., Presentation of clinically suspected persistent chlamydial infection: a case series, Int J STD AIDS, 24, pp. 469-475, (2013)
[44]  
Hocking J.S., Kong F.Y.S., Timms P., Huston W.M., Tabrizi S.N., Treatment of rectal chlamydia infection may be more complicated than we originally thought, J Antimicrob Chemother, 70, pp. 961-964, (2015)
[45]  
Bhengraj A.R., Vardhan H., Srivastava P., Salhan S., Mittal A., Decreased susceptibility to azithromycin and doxycycline in clinical isolates of Chlamydia trachomatis obtained from recurrently infected female patients in India, Chemotherapy, 56, pp. 371-377, (2010)
[46]  
O'Neill C.E., Seth-Smith H.M.B., Van Der Pol B., Harris S.R., Thomson N.R., Cutcliffe L.T., Et al., Chlamydia trachomatis clinical isolates identified as tetracycline resistant do not exhibit resistance in vitro: whole-genome sequencing reveals a mutation in porB but no evidence for tetracycline resistance genes, Microbiology, 159, pp. 748-756, (2013)
[47]  
Tormakangas L., Markkula E., Lounatmaa K., Puolakkainen M., Chlamydia pneumoniae infection in polarized epithelial cell lines, Infect Immun, 78, pp. 2714-2722, (2010)
[48]  
Shima K., Szaszak M., Solbach W., Gieffers J., Rupp J., Impact of a low-oxygen environment on the efficacy of antimicrobials against intracellular Chlamydia trachomatis, Antimicrob Agents Chemother, 55, pp. 2319-2324, (2011)
[49]  
Shima K., Klinger M., Solbach W., Rupp J., Activities of first-choice antimicrobials against gamma interferon-treated Chlamydia trachomatis differ in hypoxia, Antimicrob Agents Chemother, 57, pp. 2828-2830, (2013)
[50]  
Kutlin A., Roblin P.M., Hammerschlag M.R., In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model, Antimicrob Agents Chemother, 43, pp. 2268-2272, (1999)
123456789